|
 |
||
      |
|
|
» Apply for a Grant
- FAQs - Young Investigator - Independent Investigator - Distinguished Investigator - Staglin Award » Grantee List - Young Investigators - Independent Investigators - Distinguished Investigators - Staglin Awards
» Prizes
- Lieber Prize - Falcone Prize - Ruane Prize - Goldman-Rakic Prize - Freedman Award - Klerman Award » For Grantees - Young Investigator Fact Sheet - Independent Investigator Fact Sheet - Distinguished Investigator Fact Sheet - Staglin Award Fact Sheet 
|
 Project Summary  Donald Gordon Rainnie, Ph.D. (Young Investigator 2000) of Emory University, is testing the hypothesis that negative symptoms of schizophrenia are associated with abnormally high inhibition of a brain structure called the amygdala. This abnormality is proposed to be secondary to abnormal function of the serotonin receptor. Clozapine, a medication which appears to improve negative symptoms, blocks the serotonin type 2A (5HT-2A) receptor. Dr. Rainnie will examine whether chronic clozapine treatment acts by lowering the response of amygdala neurons to serotonin application by lowering 5HT-2A receptor expression. This work may help identify biochemical mechanisms by which clozapine leads to improve in symptoms of schizophrenia. Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Schizophrenia |
Announcements
NARSAD Award Winners
 Colleen Ann McClung, Ph.D., UT Southwestern Medical Center at Dallas, 2005 & 2007 Young Investigator Latest News from NARSAD
|
